Cover: Military Use of Drugs Not Yet Approved by the FDA for CW/BW Defense

Military Use of Drugs Not Yet Approved by the FDA for CW/BW Defense

Lessons from the Gulf War

by Richard A. Rettig

View related products

Download

Free Electronic Option

Download Individual Chapters Below

Note: Many electronic documents posted prior to 2003 are available as chapter PDFs or HTML files linked from the Contents.

Purchase

Purchase Print Copy

 FormatList Price Price
Add to Cart Paperback122 pages $20.00 $16.00 20% Web Discount

Abstract

The confrontation that began when Iraq invaded Kuwait in August 1990 brought with it the threat that chemical and biological weapons might be used against the more than half a million military personnel the United States deployed to the region. To protect these troops from such threats, the Department of Defense wished to use drugs and vaccines that, not having been tested for use in these specific situations, were considered “investigational” by the federal Food and Drug Administration. This report examines the history of the Interim Rule, adopted in December 21, 1990, that authorized the Commissioner of Food and Drugs to waive informed consent for the use of investigational drugs and vaccines for certain military uses; how this authority was used for pyridostigmine bromide and botulinum toxoid during the Gulf War; and the subsequent controversy surrounding the rule, its application, and its implications. The report then analyzes the issues the Interim Rule raised when investigational drugs are used for such purposes and makes recommendations for dealing with similar situations in the future.

Table of Contents

  • Preface HTML

  • Figures

    Figure and Tables HTML

  • Summary HTML

  • Acknowledgements

    Acknowledgments HTML

  • Glossary HTML

  • Chapter One

    Introduction HTML

  • Chapter Two

    The History of the Interim Rule HTML

  • Chapter Three

    What Uses of Drugs Are Investigational? HTML

  • Chapter Four

    The Interim Rule and Its Alternatives HTML

  • Chapter Five

    Broader Issues HTML

  • Chapter Six

    Conclusions and Recommendations HTML

  • Chapter Seven

    Postscript HTML

  • References HTML

This research was sponsored by the RAND National Security Research Division and RAND Health.

This report is part of the RAND Corporation monograph report series. The monograph/report was a product of the RAND Corporation from 1993 to 2003. RAND monograph/reports presented major research findings that addressed the challenges facing the public and private sectors. They included executive summaries, technical documentation, and synthesis pieces.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.